Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MGAM | O43451 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SI | P14410 | 1/20 | 0.33 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.33 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20101661 | 0.79 | ALDH1A1 (0.39) | ATMPOLBALDH1A1LMNAHSD17B10 | |
| SCHEMBL9660794 | 0.78 | F10 (0.39) | ATMPOLBALDH1A1LMNAHSD17B10 | |
| SCHEMBL5079235 | 0.77 | — | — | |
| SCHEMBL7359163 | 0.76 | POLB (0.33) | ATMPOLBALDH1A1LMNAHSD17B10 | |
| SCHEMBL1964683 | 0.75 | ALDH1A1 (0.39) | ATMPOLBALDH1A1LMNAHSD17B10 | |
| SCHEMBL17444931 | 0.73 | BRD4 (0.40) | ATMPOLBALDH1A1LMNAHSD17B10 | |
| SCHEMBL13640434 | 0.73 | BRD4 (0.40) | ATMPOLBALDH1A1LMNAHSD17B10 | |
| SCHEMBL3675536 | 0.73 | MAPK1 (0.33) | LMNAMEN1KMT2AMAPK1 | |
| SCHEMBL29192006 | 0.73 | ALDH1A1 (0.37) | ATMPOLBALDH1A1LMNAHSD17B10 | |
| SCHEMBL25492048 | 0.72 | BRD4 (0.39) | ATMPOLBALDH1A1LMNAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1731499-B1 | PROCESS FOR PRODUCING 1,2-CIS-2-FLUOROCYCLOPROPANE-1-CARBOXYLIC ESTER COMPOUND | DAIICHI SANKYO CO LTD (JP) | 2014-10-01 | — | — | EP | disclosed |
| US-7381833-B2 | Process for producing 1,2-cis-2-fluorocyclopropane-1-carboxylic ester compound | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-06-03 | — | — | US | disclosed |
| US-20070191626-A1 | Process for producing 1,2-cis-2 fluorocyclopropane- 1carboxylic ester compound | DAIICHI PHARMACEUTICAL CO., LTD (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1731499-A1 | PROCESS FOR PRODUCING 1,2-CIS-2-FLUOROCYCLOPROPANE-1CARBOXYLIC ESTER COMPOUND | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-12-13 | — | — | EP | disclosed |
| EP-0712831-B1 | SELECTIVE DEHALOGENATION METHOD | DAIICHI SEIYAKU CO (JP) | 1999-11-03 | — | — | EP | disclosed |
| US-5780669-A | Selective dehalogenation process | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1998-07-14 | — | — | US | disclosed |
| EP-0712831-A1 | SELECTIVE DEHALOGENATION METHOD | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1996-05-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191626-A1 | Process for producing 1,2-cis-2 fluorocyclopropane- 1carboxylic ester compound | HACL2, B2M, CA1 | ATM 3743/4885POLB 3379/4885ALDH1A1 826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.